Baudax Bio Announces Closing of $5 Million Public Offering
06 déc. 2022 16h11 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
Baudax Bio Announces Pricing of $5 Million Public Offering
02 déc. 2022 14h46 HE
|
Baudax Bio, Inc.
MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
Baudax Bio Announces 1-for-40 Reverse Stock Split
30 nov. 2022 16h50 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the...
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
08 nov. 2022 16h09 HE
|
Baudax Bio, Inc.
BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange...
Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock
19 sept. 2022 16h05 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings,...
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference
08 sept. 2022 16h05 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood,...
Baudax Bio Announces Closing of $6.2 Million Public Offering
01 sept. 2022 14h56 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
Baudax Bio Announces Pricing of $6.2 Million Public Offering
29 août 2022 22h04 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain
22 août 2022 08h00 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced today that the United States...
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights
11 août 2022 07h00 HE
|
Baudax Bio, Inc.
ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in...